NASDAQ
231.15USD
-0.05 (-0.02%)
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
14.4B
P/E
—
EPS
—
Beta
0.39
52W range
160.86-250.74
Day range
229.35–237.00
Open
232.51
Prev close
231.20
Volume
521.2K
Avg volume
641K
Dividend
0.00
IPO
2015-01-28
https://www.globenewswire.com/news-release/2026/06/13/3311416/0/en/Phase-3-Data-Show-TransCon-PTH-Replicated-Systemic-Actions-of-Endogenous-PTH-Through-Week-182-in-Adults-with-Hypoparathyroidism.html · 6/13/2026+1.00
https://seekingalpha.com/article/4909444-ascendis-pharma-rare-endocrine-compounder-entering-growth-phase-initiating-buy · 5/28/2026+1.00
https://www.globenewswire.com/news-release/2026/04/06/3268705/0/en/Ascendis-Receives-Orphan-Drug-Exclusivity-and-Launches-YUVIWEL-Navepegritide-in-the-United-States.html · 4/6/2026+1.00
https://www.defenseworld.net/2026/04/04/promising-growth-stocks-to-watch-today-april-2nd.html · 4/4/2026+0.50
https://www.defenseworld.net/2026/03/22/best-growth-stocks-to-follow-today-march-20th.html · 3/22/2026
https://www.defenseworld.net/2026/03/15/ally-bridge-group-ny-llc-acquires-shares-of-51080-ascendis-pharma-a-s-asnd.html · 3/15/2026+0.30
https://www.defenseworld.net/2026/02/08/promising-growth-stocks-to-research-february-6th.html · 2/8/2026+0.50
https://www.globenewswire.com/news-release/2026/02/04/3232456/0/en/Ascendis-Pharma-to-Report-Full-Year-2025-Financial-Results-and-Provide-Business-Update-on-February-11-2026.html · 2/4/2026+0.00
https://www.defenseworld.net/2026/01/25/promising-growth-stocks-to-consider-january-23rd.html · 1/25/2026+0.50
https://seekingalpha.com/article/4858209-ascendis-pharma-a-s-asnd-discusses-week-52-topline-results-from-coach-trial-evaluating · 1/9/2026+0.50
https://www.defenseworld.net/2025/12/14/best-growth-stocks-worth-watching-december-12th.html · 12/14/2025+0.20
https://www.benzinga.com/news/fda/25/11/49115519/ascendis-pharma-hit-by-fda-delay-as-transcon-cnp-decision-slips-to-2026 · 11/28/2025-0.30
Ascendis Pharma A/S is a biopharmaceutical enterprise dedicated to advancing therapeutic solutions for critical medical conditions that currently lack effective treatments. Its commercialized offering is SKYTROFA, a therapy prescribed for individuals suffering from growth hormone deficiency (GHD). The company boasts a robust development pipeline, featuring several TransCon-branded candidates. These include TransCon Growth Hormone (hGH), which is being progressed for pediatric GHD patients in Japan and for adults with GHD. Also under development are TransCon parathyroid hormone for adults with hypoparathyroidism, and TransCon CNP, aimed at treating pediatric achondroplasia. Further expanding its innovative portfolio, Ascendis is also developing a TransCon toll-like receptor (TLR) 7/8 agonist for intratumoral administration, alongside TransCon IL-2 ß/g, designed for systemic delivery. Founded in 2006, this enterprise maintains its corporate headquarters in Hellerup, Denmark.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
